ExchangeDEX+

Buy Crypto Markets Spot FuturesGOLD Earn Event Center

Galderma unveils We Are All Sculptra, a global campaign capturing the clinical performance of Sculptra® across nine diverse patient profiles and journeys, over Galderma unveils We Are All Sculptra, a global campaign capturing the clinical performance of Sculptra® across nine diverse patient profiles and journeys, over

We Are All Sculptra: First-of-its-Kind Galderma Initiative to Demonstrate How Everyone Can Benefit from Sculptra’s Regenerative Properties

Author: AI Journal

Source: AI Journal

2026/02/12 14:15

8 min read

PROVE$0.3245+5.08%

Galderma unveils We Are All Sculptra, a global campaign capturing the clinical performance of Sculptra^®across nine diverse patient profiles and journeys, over two years¹
Backed by over 25 years of clinical use, Sculptra continues to prove its versatility as a regenerative treatment that works across all three layers of the skin^2-6
The campaign captures the patients’ clinical and emotional experiences – including before & after treatment imagery – highlighting Sculptra’s adaptability and reinforcing its role in tailored, science-backed regenerative aesthetic care¹

ZUG, Switzerland–(BUSINESS WIRE)–Galderma (SIX: GALD), the pure-play dermatology category leader, today unveiled We Are All Sculptra, a unique program designed to capture the clinical impact of Sculptra^® across nine diverse patients – who were all new to injectable aesthetics – over two years.¹ This innovative initiative will offer a rare and authentic real-life perspective on the power of regenerative biostimulation to deliver personalized outcomes, and demonstrate how Sculptra adapts to different skin types, life stages, and aesthetic goals.¹

Sculptra is the first proven regenerative biostimulator, backed by over 25 years of clinical use.^2-6 With a unique poly-L-lactic acid (PLLA-SCA) formulation, Sculptra re-engages the skin’s renewal process, stimulating collagen and elastin for healthy looking skin.^3,7-11 Over the decades, it has evolved into a versatile treatment that delivers regenerative benefits across all three skin layers, helping to gradually restore volume, firmness, radiance and skin quality, and smoothing wrinkles and folds over time.^2,3,7-14

“What excites me about this unique program is how it aims to capture the nuance of clinical practice: different protocols, different goals, and different outcomes, all unified by a science-first approach to aesthetic personalization. And beyond the science, we also notice an emotional journey – seeing patients regain confidence, feel more like themselves, and experience a deeper sense of wellbeing as their natural beauty is restored over time.”

MS. PRIYANKA CHADHA, FRCS (PLAST)
CONSULTANT PLASTIC SURGEON, GLOBAL EDUCATOR

AMER CLINIC, LONDON

Through self-recorded video diaries and clinical check-ins, We Are All Sculptra will follow nine patients – who were all new to injectable aesthetics – over two years, offering a long-term view of how Sculptra performs over time.¹ Its launch captures the patients’ personal reflections, results, and before & after treatment imagery, offering a powerful lens into both clinical outcomes and emotional impact.¹

The campaign highlights the rich diversity of real patients, spanning age, gender identity, ethnicity, and skin biology.¹ Grounded in Galderma’s AART (Assessment, Anatomy, Range, and Treatment) methodologies and HIT (Holistic Individualised Treatment) protocols, it demonstrates the extent to which regenerative aesthetics can be tailored to individual goals and skin needs, by combining structured clinical assessment with holistic, individualized treatment planning.¹

Whether renewing natural volume, improving skin quality, or repositioning tissue for a lifted appearance, each case will highlight Sculptra’s adaptability across diverse indications and patient needs.¹ As well its natural, long-lasting clinical outcomes, the campaign captures the emotional resonance of treatment, with improved confidence, self-recognition, and wellbeing seen throughout the group, while also leaving them with a positive first impression of aesthetic treatments.¹

“With We Are All Sculptra, we’ll redefine what regenerative biostimulation looks like in real life. This program is a bold expression of Galderma’s commitment to science-led personalization, showcasing how Sculptra performs across diverse skin types, treatment approaches, and patient goals. It’s not just about representation; it’s about proving that versatility and inclusivity are inseparable in modern aesthetic medicine.”

ALAN D. WIDGEROW, MBBCH, MMED, FCS, FACS

CHIEF SCIENTIFIC OFFICER GALDERMA, HEAD SKIN SCIENCE CENTER FOR INNOVATION

Learn more about We Are All Sculptra here.

About Sculptra

Sculptra is the first proven regenerative biostimulator, with a unique poly-L-lactic acid (PLLA-SCA) formulation, to provide progressive and sustained regenerative effect across all three skin layers.^2-6Sculptra reverses aging processes in the skin, including degradation of the extracellular matrix, which results in volume loss, laxity, and the appearance of wrinkles.^2,15-18 Sculptra progressively rebuilds the skin’s structural foundation by encouraging the remodeling of components of the extracellular matrix, such as elastin and collagen, helping to gradually restore volume, firmness, radiance and skin quality, and the look of fullness to wrinkles and folds over time.^8-11Sculptra has been shown to provide visible improvements as early as one month after treatment, with results lasting up to two years.^2,17,19,20

About Galderma

Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

References

1.		Galderma. Data on file. We Are All Sculptra. 2025
2.		U.S. Food and Drug Administration. Sculptra summary of safety and effectiveness data. Available online. Accessed December 2025.
3.		Zhang Y, et al. In vivo inducing collagen regeneration of biodegradable polymer microspheres. Regen Biomater. 2021;8(5):rbab042. doi: 10.1093/rb/rbab042.
4.		Waibel J, et al. A randomized, comparative study describing the gene signatures of poly-L-lactic acid (PLLA-SCA) and calcium hydroxylapaptite (CaHA) in the treatment of nasolabial folds. Poster presented at IMCAS World Congress; February 3-6. 2024; Paris, France.
5.		Huth S, et al. Molecular insights into the effects of PLLA-SCA on gene expression and collagen synthesis in human 3d skin models containing macrophages. J Drugs Dermatol. 2024;23(4):285-288. doi: 10.36849/JDD.7791.
6.		Zubair R, et al. SPLASH: Split-body randomized clinical trial of poly-L-lactic acid for adipogenesis and volumization of the hip dell. Dermatol Surg. 2024;50(12):1155-1162. doi: 10.1097/DSS.0000000000004417.
7.		Widgerow A, et al. A randomized, comparative study describing the gene signatures of Poly-L-Lactic Acid (PLLA-SCA) and Calcium Hydroxylapaptite (CaHA) in the treatment of nasolabial folds. Poster presented at IMCAS World Congress, February 1-3, 2024, Paris, France.
8.		Waibel J, et al. Gene Analysis of Biostimulators: PLLA-SCA Triggers Regenerative Morphogenesis while CaHA-R Induces Inflammation upon Facial Injection. Poster presented at ASDS 2024, October 17-20, 2024, Orlando, Florida, United States.
9.		Waibel J, et al. Bulk RNA-seq Analysis of Poly-L-Lactic Acid (PLLA-SCA) vs Calcium Hydroxyapetite (CaHA-R) Reveals a Novel, Adipocyte Mediated Regenerative Mechanism of Action Unique to PLLA. Poster presented at ASDS 2024 Annual Meeting, October 17-20, 2024, Orlando, Florida, United States.
10.		Haddad S, et al. Evaluation of the biostimulatory effects and the level of neocollagenesis of dermal fillers: a review. Int J Dermatol. 2022;61:1284–1288. doi: 10.1111/ijd.16229.
11.		Vleggaar D, et al. Consensus recommendations on the use of injectable poly-L-lactic-acid for facial and nonfacial volumization. J Drugs Dermatol. 2014;13(4 Suppl):s44–s51.
12.		Narins RS, et al. A randomized study of the efficacy and safety of injectable poly-L-lactic acid versus human-based collagen implant in the treatment of nasolabial fold wrinkles. J Am Acad Dermatol. 2010;62(3):448–62. doi: 10.1016/j.jaad.2009.07.040.
13.		Galderma. Data on File (MA-47133).
14.		Mu X, et al. 12-Month Effectiveness and Safety of PLLA Treatment of Midface in Chinese Subjects: A Multicenter, Randomized, No-Treatment Controlled Study. Presented at AMWC. March 30 to April 1, 2023. Monte-Carlo, Monaco.
15.		Zhang S and Duan E. Fighting against skin aging: the way from bench to bedside. Cell Transpl. 2018;27(5):729-738. doi: 10.1177/0963689717725755.
16.		Shuster S, Black MM, and McVitie E. The influence of age and sex on skin thickness, skin collagen and density. Br J Dermatol. 1975;93(6):639-643. doi: 10.1111/j.1365-2133.1975.tb05113.x.
17.		Goldberg D, et al. Single-arm study for the characterization of human tissue response to injectable poly-L-lactic acid. Dermatol Surg. 2013;39:915–922. doi: 10.1111/dsu.12164.
18.		Zarbafian M, et al. The emerging field of regenerative aesthetics—where we are now. Dermatol Surg. 2022;48:101–108. doi: 10.1097/DSS.0000000000003239.
19.		Hexsel D, Hexsel CL, and Cotofana S. Introducing the L-Lift: A Novel Approach To Treat Age-Related Facial Skin Ptosis Using A Collagen Stimulator. Dermatol Surg. 2020;46(8):1122-1124. doi: 10.1097/DSS.0000000000002015.
20.		Fabi S, et al. 24-month clinical trial data on effectiveness and safety after correction of cheek wrinkles using a biostimulatory poly-L-lactic acid injectable implant. Poster presented at AMWC. March 30 – April 1, 2023. Monte-Carlo, Monaco.

Contacts

For further information:
Christian Marcoux, M.Sc.
Chief Communications Officer
[email protected]
+41 76 315 26 50

Richard Harbinson
Corporate Communications Director
[email protected]
+41 76 210 60 62

Céline Buguet
Franchises and R&D Communications Director
[email protected]
+41 76 249 90 87

Emil Ivanov
Head of Strategy, Investor Relations, and ESG
[email protected]
+41 21 642 78 12

Jessica Cohen
Investor Relations and Strategy Director
[email protected]
+41 21 642 76 43

Market Opportunity

Succinct Price(PROVE)

$0.3245

$0.3245$0.3245

+4.34%

USD

Succinct (PROVE) Live Price Chart

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

Tags:

#DeFi